The Asthma Landscape in the UK
Around 5.4 million people in the UK receive treatment for asthma, according to NHS figures. That is roughly one in every twelve adults and one in every eleven children. Among them, an estimated 5% to 10% live with severe asthma, a form of the condition that does not respond well to high-dose inhaled corticosteroids and often requires frequent courses of oral steroids or hospital visits.
The burden falls unevenly. Research from the UK Severe Asthma Registry (UKSAR) shows that people with severe asthma account for a disproportionate share of emergency admissions and healthcare costs, despite making up a small fraction of the total asthma population. The same registry has been instrumental in tracking how treatments perform outside the controlled environment of a trial, providing real-world evidence that has already shifted clinical practice.
Clinical trials sit at the centre of this picture. They are not just about testing experimental drugs. Many UK trials examine how existing treatments can be used more effectively, whether digital tools can improve self-management, or how environmental factors like air pollution interact with asthma control.
What Asthma Trials Actually Look Like
Asthma trials in the UK fall into several broad categories. Drug trials, particularly for biologics like dupilumab, benralizumab, and mepolizumab, dominate the landscape. These injectable medications target specific inflammatory pathways involved in severe asthma, and UK centres have been heavily involved in both the pivotal phase 3 studies and the long-term follow-up work that followed.
Observational studies are equally common. The Manchester Asthma and Allergy Study (MAAS), for instance, has been tracking a birth cohort in the north-west of England for over two decades, examining how genetic and environmental factors shape respiratory health from childhood into adulthood. This kind of research does not involve an experimental treatment; participants simply allow researchers to collect data over time, and the insights have been invaluable.
Then there are trials focused on delivery. A recent randomised controlled trial coordinated through the University of Oxford is testing whether a digital social intervention, promoted by GP practices, can improve asthma control in adults. Instead of a new drug, the intervention uses online peer support and education, reflecting a growing interest in non-pharmacological approaches.
The Children's Anti-Inflammatory Reliever Study (CARE-UK), running out of Imperial College London, is examining whether a different type of reliever inhaler can reduce the frequency of asthma attacks in children. It is one of several paediatric trials currently recruiting across the UK, and it highlights how research extends well beyond the severe adult population.
Who Can Take Part, and What to Expect
Eligibility varies enormously from trial to trial. Some studies recruit only people with severe eosinophilic asthma who have already tried multiple treatments. Others are open to anyone with a GP diagnosis of asthma, regardless of severity. Age, lung function, smoking history, and current medication use all factor into the screening process.
The screening itself is thorough. You can expect blood tests, lung function assessments like spirometry, and a detailed review of your medical history. Some trials require a bronchoscopy or a CT scan. The purpose is twofold: to confirm that you meet the study criteria and to establish a baseline against which any changes can be measured. It is worth knowing that being screened does not guarantee enrolment. Many people are ruled out at this stage, often because their asthma turns out to be milder than anticipated or because a specific blood marker does not reach the threshold.
Once enrolled, the commitment varies. A short-term drug trial might last six months with monthly clinic visits. A long-term safety follow-up could stretch over several years. Some observational studies require little more than an annual questionnaire. Travel costs are typically reimbursed, and some trials offer compensation for time, though the amounts are modest and should not be the primary motivation.
Safety monitoring is continuous. Every trial running in the UK must be approved by an NHS Research Ethics Committee and, where applicable, the Medicines and Healthcare products Regulatory Agency (MHRA). Participants are free to withdraw at any point without affecting their routine care.
Finding a Trial That Fits
The most straightforward starting point is the REACH register (Register for Asthma Research), run by the Asthma UK Centre for Applied Research. REACH is a database of people across the UK who have expressed interest in taking part in asthma studies. Once registered, you are only contacted when a study matches your profile, and there is no obligation to participate. It is a low-effort way to keep the door open without committing to anything upfront.
For those who prefer to search actively, ISRCTN Registry and ClinicalTrials.gov list studies worldwide, with filters for location, condition, and recruitment status. Searching for "asthma" and "United Kingdom" on either platform returns dozens of active trials. The Be Part of Research website, run by the National Institute for Health and Care Research (NIHR), offers a more user-friendly interface and is designed specifically for the UK public.
Your GP or consultant can also be a useful route. Many severe asthma centres in the UK—including those at Guy's and St Thomas' in London, Wythenshawe Hospital in Manchester, and the Queen Elizabeth Hospital in Birmingham—have dedicated research teams who can discuss available trials during routine appointments.
A Closer Look at Trial Types
| Trial Type | What It Involves | Typical Duration | Ideal For | Key Considerations |
|---|
| Biologic drug trial | Injectable medication, regular blood tests, clinic visits | 6–24 months | Adults with severe, uncontrolled asthma | May require tapering of existing steroids; placebo arm possible |
| Digital intervention trial | App-based or online support, questionnaires | 3–12 months | Any adult with asthma on a GP register | Low time commitment; no experimental drug exposure |
| Observational cohort study | Periodic health assessments, no treatment change | 1–20+ years | Anyone with a confirmed asthma diagnosis | No direct benefit to participant; vital for long-term research |
| Paediatric trial | Age-appropriate assessments, parental involvement | 6–18 months | Children with asthma (age varies by study) | Requires parental consent; child-friendly design |
| Inhaler device comparison | Using different inhalers, lung function monitoring | 3–6 months | Adults and children able to use inhalers independently | Often compares existing rather than experimental treatments |
Not every trial suits every person. Talking through the options with a research nurse or your respiratory team can clarify what is realistic and what the day-to-day experience would involve.
Real Stories from the Research Community
Sarah, a 42-year-old teacher from Leeds, had been on high-dose inhaled steroids for over a decade and still experienced three or four exacerbations each year. Her consultant suggested a biologic trial at a nearby severe asthma centre. After a screening period of four weeks, she was enrolled in a study comparing benralizumab to placebo. "I noticed a difference within two months," she says. "The morning chest tightness just stopped. I went from dreading winter to barely thinking about my asthma." When the trial concluded, she transitioned to the same medication through routine NHS prescribing.
Not every experience is dramatic. Mark, a 56-year-old accountant in Glasgow, joined an observational study through the UKSAR network. "They took some blood, did a breathing test, and I answered questions about my symptoms every six months. It was very low-key. I didn't get a miracle treatment out of it, but I did get a much better understanding of my own lung function." He continues to participate because he values the contribution to research.
These stories reflect the range of what clinical trials can offer. Some participants access cutting-edge treatments years before they become widely available. Others gain nothing more than a clearer picture of their own health. Both outcomes matter.
Practical Steps to Get Started
Speak to your GP or asthma nurse first. They can confirm whether your asthma is well-characterised and whether you meet the basic criteria for trial participation. If you are already under a hospital consultant, that conversation may be even more productive, as secondary care teams are often directly involved in research.
Register with REACH. The process takes about fifteen minutes online and requires basic information about your diagnosis, medications, and contact preferences. It is not a commitment to anything, and your details are stored securely.
Browse the NIHR Be Part of Research website. Unlike the larger international registries, it is tailored to UK residents and clearly states which studies are recruiting and where.
Consider the practicalities. If a trial requires weekly visits to a centre in central London and you live in rural Devon, the logistics may not be sustainable. Ask about travel support and the expected number of visits before committing.
Ask questions. A good research team will welcome them. How long has this treatment been studied in humans? What happened in earlier trials? What are the known side effects? What happens when the trial ends? The answers should be clear and honest.
The UK has one of the most active asthma research communities in the world, and the infrastructure supporting it—from the UK Severe Asthma Registry to the REACH network—is designed to connect patients with opportunities. Whether you are looking for a new treatment option, a better understanding of your condition, or simply a way to contribute to research that could help others, the path begins with a conversation.
研究の知恵